Anti-Mouse CD317 [Clone 927] — Purified in vivo GOLD™ Functional Grade

Clone 927 is a monoclonal antibody that targets mouse CD317 (BST2, PDCA-1) and is most commonly used in vivo to specifically deplete plasmacytoid dendritic cells (pDCs) and block interferon-alpha (IFN-α) secretion by these and other IFN-producing cells in mice.

Key in vivo applications of clone 927 in mice include:

• Depletion of plasmacytoid dendritic cells (pDCs): Clone 927 is highly effective at depleting pDCs (also known as IFN-producing cells or IPCs) from mouse tissues, achieving depletion rates of about 95%.
• Functional blockade of IFN-α secretion: The antibody effectively blocks the secretion of interferon-alpha by pDCs and other IFN-producing cells, which is important for studying immune regulation and the role of these cytokines in various disease models.

Common experimental contexts for clone 927 in vivo:

• Tumor immunology: Used to evaluate the role of pDCs and IFN-α in the tumor microenvironment and anti-tumor immunity.
• Infectious disease models: Applied in mouse models of viral or bacterial infection to understand how pDCs and IFN responses modulate host defense and pathogenesis.
• Autoimmunity research: Utilized in studies of autoimmune diseases to assess the impact of pDC depletion and IFN blockade on disease induction and progression.
• Functional studies of immune cell populations: By depleting pDCs, researchers can dissect their specific contributions to immune responses in a variety of in vivo settings.

Additional notes:

• Antigen distribution: CD317 (PDCA-1) is primarily a marker for pDCs under steady-state conditions but is also upregulated on many immune cell types following stimulation (e.g., via influenza, CpG, LPS, viral infection).
• Exclusivity: While pDC depletion is the most prominent application, clone 927 can also impact other cells under certain inflammatory or viral challenge conditions where CD317 is induced on additional cell types.

In summary, clone 927 is a fundamental tool for in vivo depletion of plasmacytoid dendritic cells and inhibition of their IFN-α secretory function in mouse models, principally employed in studies of immunity, infection, cancer, and autoimmune diseases.

The antibody known as clone 927 targets mouse CD317 (also called BST2 or PDCA-1) and is widely used as a specific marker for plasmacytoid dendritic cells (pDCs) in mice. In the literature, several other antibodies and protein markers are commonly used in combination with 927, especially in immunophenotyping and depletion studies. The most frequently co-used markers are:

• CD11c: A classical marker for dendritic cells, often used alongside 927 to better define pDC populations or distinguish pDCs from conventional dendritic cells (cDCs).
• B220 (CD45R): Frequently combined in flow cytometry panels to identify pDCs as CD317+ B220+ cells; helps differentiate pDCs from other B cells and dendritic cell subsets (inferred from common immunological protocols).
• CD19: Used to exclude B cells in gating strategies when characterizing pDCs with CD317/927 antibody (inferred from published gating strategies).
• Siglec-H: Another pDC marker sometimes used with 927 for greater specificity and confirmation of pDC identity (inferred from common use in the field).

Key proteins and antibodies typically encountered with 927:

• CD11c — Distinguishes between pDCs and other dendritic cell types.
• B220 (CD45R) — Confirms hematopoietic origin and helps define pDCs within lymphoid organs.
• Siglec-H — Additional marker confirming pDC identity.
• CD19 and/or CD3 — Used to exclude B cells and T cells, respectively, in flow cytometry sorting panels and analyses.

These combinations are standard in flow cytometry and cell depletion experiments for mouse immune system studies, especially when focusing on the selective identification, quantification, or depletion of pDCs.

If your context is outside mouse immunology or pDC identification, please clarify for more tailored combinations.

The key findings from scientific literature on clone 927 mainly concern its use as a monoclonal antibody to identify and deplete murine plasmacytoid dendritic cells (pDCs), also referred to as interferon-producing cells (IPCs), by targeting the cell surface marker CD317 (BST2, PDCA-1).

Key findings include:

• Specific Recognition and Depletion: Clone 927 specifically recognizes CD317, a marker for murine pDCs under naïve conditions, allowing for their identification and depletion in experimental models. Administration of clone 927 in vivo depletes pDCs by approximately 95% and abrogates IFN-α secretion by IPCs in response to CpG stimulation, thereby significantly reducing plasma cells and type I interferon production.

• Research Applications: The clone facilitates mechanistic studies in tumor immunology, infection, and autoimmunity by enabling targeted depletion of pDCs, which are early responders to viral infection and crucial in directing both innate and adaptive immune responses.

• Mechanism and Specificity: CD317 is present mainly on the cell surface of IPCs in naïve mice, with expression on both resting and activated IPCs being independent of interferons. However, upon stimulation with type I IFNs and IFN-γ, CD317 expression is induced on most cell types.

• Development and Screening: Clone 927 was developed to address difficulties in identifying and studying IPCs due to their rarity and complex phenotype in murine tissues. The antibody is a rat IgG2b isotype, generated by immunizing rats with bone marrow-derived IPCs.

• Broader Relevance of CD317: CD317 (BST2/tetherin) is expressed on a variety of immune cells, including T cells, B cells, mast cells, NK cells, and is involved in B-cell development and functions related to virus restriction, such as inhibiting retrovirus release—including HIV-1—by causing retention of virions, which can impact viral pathogenesis and therapeutic strategies.

Summary Table: Biological Role and Research Utility of Clone 927

In summary, citations for clone 927 focus on its essential role in selectively identifying and depleting murine pDCs via CD317 for immunological research, thereby enabling critical mechanistic insights into innate immunity and viral responses.

Dosing regimens of clone 927 (anti-mouse CD317/BST2, also known as PDCA-1) in mouse models typically involve intraperitoneal (IP) injection of 200–250 μg per mouse, given 2–3 times per week. These regimens are commonly used for depletion of plasmacytoid dendritic cells (pDCs) in vivo.

Key context and details:

• There is no universally standardized protocol for clone 927; the dosing may be adjusted based on the experimental goal, mouse strain/model, and the outcome to be studied.
• Most published protocols and product recommendations cite 200–250 μg IP injection per dose, with the frequency of 2–3 times weekly (e.g., every 2–3 days).
• This approach is effective for robust depletion of pDCs (over 90%) and abrogation of IFN-α secretion in response to stimuli such as CpG.
• Regimen details often do not vary significantly between major mouse models (e.g., C57BL/6, BALB/c), but doses might be fine-tuned in specific disease contexts or with co-administered agents. Direct comparisons of dose optimization across mouse strains are rarely published.
• In influenza and infection models, this regimen effectively depletes targeted populations, though occasional studies may alter dose or frequency depending on particular experimental requirements.
• The isotype of clone 927 is rat IgG2b, and it is often used in combination with other immunological interventions for mechanistic studies.

Summary table: Typical clone 927 dosing in mouse models

Published studies and antibody suppliers suggest starting at 200–250 μg IP, 2–3 times weekly, and adjusting only as necessary for model-specific results. No major deviations in regimen have been described for specific mouse strains or disease models; reported adjustments are experimental rather than standard.